By Chris Wack
ImmunityBio shares advanced 17% to $3.34 after the company said the Food and Drug Administration awarded a regenerative medicine advanced therapy designation for Anktiva and CAR-NK for the reversal of lymphopenia in patients receiving standard-of-care chemotherapy/radiotherapy.
The immunotherapy company said the treatment is also for patients with multiply relapsed locally advanced or metastatic pancreatic cancer. The designation follows clinical data and significant overall survival correlations in multiple trials across multiple tumor types.
ImmunityBio said it intends to submit a Biologic License Application for the indication of reversal of lymphopenia in patients receiving standard-of-care chemotherapy and/or radiation and for the treatment of locally advanced or metastatic pancreatic cancer, which includes the first-in-class CAR-NK.
In the authorization letter, the FDA has committed to work closely with ImmunityBio to provide guidance and advice on generating the evidence needed to "support approval" of the indication above "in an efficient manner."
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
February 28, 2025 11:14 ET (16:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。